The U.S. Food and Drug Administration has approved American Gene Technologies to begin phase one human trials of a gene therapy call AGT103-T, a potential cure for HIV.
“This is momentous news that we have FDA approval to launch Phase 1 and conduct our first human trials. We are beyond excited to reach this milestone. This brings us closer to our goal of transforming lives with genetic medicines,” said Chief Science Officer David Pauza in a statement.
While the treatment has promise, some critics have urged caution and called for AGT to tone down their rhetoric as many clinical trails routinely fail during phase one.